StreetInsider.com News Articles

Form 15-12G Anebulo Pharmaceuticals,

Mon, 02 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260302/26092795.html

Form 15-12G Anebulo Pharmaceuticals,

Mon, 02 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260302/26092795.html

Form 25 Anebulo Pharmaceuticals,

Tue, 17 Feb 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260217/26014608.html

Form 25 Anebulo Pharmaceuticals,

Tue, 17 Feb 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260217/26014608.html

Form SCHEDULE 13G/A Anebulo Pharmaceuticals, Filed by: Nantahala Capital Management, LLC

Fri, 13 Feb 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260213/26001735.html

Form SCHEDULE 13G/A Anebulo Pharmaceuticals, Filed by: Nantahala Capital Management, LLC

Fri, 13 Feb 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260213/26001735.html

Form 10-Q Anebulo Pharmaceuticals, For: Dec 31

Thu, 12 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260212/25992543.html

Form 10-Q Anebulo Pharmaceuticals, For: Dec 31

Thu, 12 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260212/25992543.html

Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q2 EPS by 8c

Thu, 12 Feb 2026 16:16:10 -0400

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported Q2 EPS of ($0.05), $0.08 better than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Anebulo Pharmaceuticals, Inc. (ANEB) click here.

Form 8-K Anebulo Pharmaceuticals, For: Feb 12

Thu, 12 Feb 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260212/25992118.html

Form 8-K Anebulo Pharmaceuticals, For: Feb 12

Thu, 12 Feb 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260212/25992118.html

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Thu, 12 Feb 2026 16:15:00 -0400

Second Quarter Fiscal Year 2026 and Subsequent Highlights:

On February 6, 2026, Anebulo announced that the Company’s board of directors (the “Board”) approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission (“SEC”) in order

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Thu, 12 Feb 2026 16:15:00 -0400

Second Quarter Fiscal Year 2026 and Subsequent Highlights:

On February 6, 2026, Anebulo announced that the Company’s board of directors (the “Board”) approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission (“SEC”) in order

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Thu, 12 Feb 2026 16:15:00 -0400

Second Quarter Fiscal Year 2026 and Subsequent Highlights:

On February 6, 2026, Anebulo announced that the Company’s board of directors (the “Board”) approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission (“SEC”) in order

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Thu, 12 Feb 2026 16:15:00 -0400

Second Quarter Fiscal Year 2026 and Subsequent Highlights:

On February 6, 2026, Anebulo announced that the Company’s board of directors (the “Board”) approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission (“SEC”) in order

Form 8-K Anebulo Pharmaceuticals, For: Feb 05

Fri, 06 Feb 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260206/25959063.html

Form 8-K Anebulo Pharmaceuticals, For: Feb 05

Fri, 06 Feb 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260206/25959063.html

Anebulo Pharmaceuticals to delist from NASDAQ and deregister with SEC

Fri, 06 Feb 2026 09:00:34 -0400

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its board of directors approved the voluntary delisting of the company's common stock from The Nasdaq Capital Market and subsequent deregistration with the U.S. Securities and Exchange Commission.

The clinical-stage pharmaceutical company, which develops treatments for acute cannabis-induced toxic effects, notified Nasdaq of its intention to voluntarily delist its shares. Anebulo plans to file a Form 25 with the SEC on or about February 17, 2026, with the delisting expected to become effective February 27, 2026.

The company intends to file a Form 15 with the SEC on or about February 27, 2026, certifying it has

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Fri, 06 Feb 2026 09:00:00 -0400

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company’s board of directors (the “Board”) has approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission (“SEC”) in order to terminate and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Simultaneously with this announcement, Anebulo notified Nasdaq

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Fri, 06 Feb 2026 09:00:00 -0400

Simultaneously with this announcement, Anebulo notified Nasdaq

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Fri, 06 Feb 2026 09:00:00 -0400

Simultaneously with this announcement, Anebulo notified Nasdaq

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Fri, 06 Feb 2026 09:00:00 -0400

Simultaneously with this announcement, Anebulo notified Nasdaq

Form SC TO-I/A Anebulo Pharmaceuticals, Filed by: Anebulo Pharmaceuticals, Inc.

Thu, 29 Jan 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260129/25913389.html

Form SC TO-I/A Anebulo Pharmaceuticals, Filed by: Anebulo Pharmaceuticals, Inc.

Thu, 29 Jan 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260129/25913389.html

Form 8-K Anebulo Pharmaceuticals, For: Jan 29

Thu, 29 Jan 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260129/25913357.html